expression ( 1, 2) . The abundance ofsomatotroph IGF-I receptors appears to be a major determinant of GH secretion in response to IGF-I (3) . Defects in endocrine receptors may underly several pathophysiologic states. Heterozygote individuals expressing both wild-type (WT) and mutant thyroid hormone receptors and wild-type or tyrosine kinase defective surface insulin receptors have been described (4) (5) (6) (7) . These patients exhibit thyroid hormone or insulin resistance, respectively. Recent reports demonstrate that defective epidermal growth factor (8, 9) , platelet-derived growth factor (10) , fibroblast growth factor ( 11 ), and c-kit ( 12) receptors function as dominant negative mutants suppressing the response of normal receptors in the same cell. These growth factor receptors dimerize in the presence of ligand and are noncovalently associated. In contrast, insulin and IGF-I receptors are covalently linked by disulfide bonds independent ofligand binding. Overexpression of a truncated insulin receptor lacking kinase activity inhibited insulin-stimulated tyrosine phosphorylation of putative substrates and results in diminished sensitivity of transfected cells to insulin ( 13 ) . Wild-type-mutant receptor hybrid formation offers an explanation for the observed inhibition of endogenous receptor function both in vivo and in vitro. Intact rat/human hybrid insulin receptor formation as well as intact insulin/IGF-I hybrids have been demonstrated both in vivo and in cell-free systems (14) (15) (16) .
We have previously reported that overexpression of the intact 90Tyr (WT) human IGF-I receptor cDNA in rat pituitary GC cells results in enhanced responsiveness of transfectants to the IGF-I signal ( 17 (CSA, 1, 049 ci/mmol) in 5 ml of serum-free methionine-free medium. After 16 h, the cells were lysed in lysis buffer (0.01 M NaCl, 0.5% deoxycholate, 1% Triton X-100, 0.1% SDS, 0.01% sodium azide, and 1 mM phenylmethylsulfonyl fluoride), and centrifuged at 3,000 rpm for 15 min at 4°C. Either aIR3 or Ab 1-2 were used at 1:500 or a 1:300 final concentrations, respectively. Immune complexes were precipitated with protein A-Sepharose (Pharmacia, Inc., Piscataway, NJ). The pellets were then washed and loaded onto 4% nondenaturing polyacrylamide SDS gels along with prestained protein molecular weight markers (Bethesda Research Laboratories, Gaithersburg, MD). For studies of the IGF-I receptor biosynthetic half-life, semiconfluent cells were metabolically labeled with [3Sj]methionine as described. After 16 h, medium was replenished with serum-free defined medium containing methionine with or without 6.5 nM IGF-I. After further incubation at 37°C, the cells were harvested at the indicated time points and processed as described above.
GH secretion. 5 X 105 cells were plated on 9-cm2 multiwells and grown for 24 h in growth medium. Medium was then aspirated monolayer washed twice with PBS, and replenished with 1.5 ml ofserum-free defined medium with or without IGF-I 6.5 nM. Aliquots of medium were removed at the indicated time points and assayed for rat GH using RIA reagents kindly provided by the National Hormone and Pituitary Program, NIDDK (Bethesda, MD). ( 19) . The 460-kD 9"Tyr( WT) human holotetramer, the 360-kD rat/mutant human hybrid and 300-kD mutant human holotetramer were recognized in 950Tyr (WT ) and 952STOP cells respectively (Fig. 2) . The intact IGF-I receptor human holotetramer was immunoprecipitated by both aIR3 and antibody Ab 1-2 in 950Tyr (WT) cells as expected. aIR3 precipitated the truncated (952STOP) human receptor holotetramer, but only Ab 1-2 recognized the rat/mutant human hybrid receptor. The ratio of hybrid receptors to endogenous rat receptor proteins suggests that the majority of endogenous IGF-I receptors are in hybrid formation with the overexpressed mutant human IGF-I receptors.
IGF-I receptor biosynthetic half-life. 9"0Tyr (WT) and truncated 952STOP transfectants were labeled with [3S]methionine for 16 h. Medium was then changed and pulse chase experiments performed for up to 16 h in the presence or absence of IGF-I ligand (6.5 nM) (Fig. 3) . Half-life of9"0Tyr (WT) human receptors was > 6 h. Densitometric scanning reveals a 90% increase in receptor degradation by 16 h. The addition of ligand appeared not to influence the rate of degradation of the receptors. In cells expressing mutant receptors (952STOP), hybrid receptor degradation rates were clearly slower, and by 16 h the majority of synthesized receptors were still present (Fig. 3  b) . Similarly, the presence of ligand did not affect the hybrid receptor half-life. Mutant human IGF-I holotetramers also appeared to degrade at a slower rate, similar to the slow degradation of rat/mutant human hybrid receptors (Fig. 3 c) . The apparent reduction in receptor mass in the presence ofligand is 2118 Prager et al. due to competition between IGF-I and a IR3 antibody for binding to the a subunit ( 19) , rather than increased degradation.
Ligand-induced receptor autophosphorylation and phosphorylation of endogenous substrate. Cells expressing either "50Tyr (WT) or truncated receptors were incubated in the presence or absence of IGF-I 6.5 nM for 1 min at 370C. The transfectants were then lysed, immunoprecipitated with monoclonal anti-phosphotyrosine antibody, and electrophoresed on SDS-polyacrymide gels. In the presence of IGF-I, the a and subunits of the IGF-I receptor as well as the predicted ppl 83 substrate of the receptor were detected in cells overexpressing "0Tyr (WT) IGF-I receptors (Fig. 4) . The 952STOP transfectants failed to undergo ligand-mediated IGF-I receptor autophosphorylation anA endogenous protein phosphorylation.
["S] methionine labeling of the a subunit is less intense than that ofthe ,B subunit consistent with the 1:2 ratio ofmethionine residues in the subunits. The a subunit ofthe IGF-I receptor is immunoprecipitated by anti-phosphotyrosine antibodies despite the absence of phosphorylation on its tyrosine residues because of the disulfide bond between the a and phosphorylated receptor subunits. IGF-I receptor signaling. To determine the effect of hybrid receptor formation on endogenous rat IGF-I receptor function, pituitary IGF-I receptor signaling was tested. Cells were treated with IGF-I (6.5 nM) and GH secretion measured. After 18 h of IGF-I treatment, untransfected cells only suppressed GH by 20%, whereas 950Tyr (WT) transfectants already exhibited a 58% suppression of GH secretion as previously reported (17, 18) . 952STOP cells failed to suppress GH secretion (Fig. 5) . By 36 h, untransfected cells showed a 40% suppression ofGH, and overexpressing 950Tyr (WT) transfectants a 60% suppression of GH as expected. However, 952STOP cells still failed to respond to the IGF-I ligand (6.5 nM) and in fact, GH secretion was higher in these cells than in nontransfected control cells despite the presence of endogenous IGF-I receptors (P < 0.001 ). The mutant 952STOP cells were therefore completely devoid ofbiological signaling to GH despite the presence of endogenous rat IGF-I receptors. These observations imply that 952STOP be- haves as a dominant negative inhibitor of endogenous IGF-I receptor function.
Discussion
In this report we describe a model system which allowed analysis of endogenous rat/mutant human hybrid IGF-I receptors, using pituitary cell lines which express a mixed population of (20) . The monoclonal human aIR3 antibody bound to human IGF-I receptors, but did not bind to the endogenous rat IGF-I receptors and only bound weakly to the rat/human hybrid. The 360-kD IGF-I receptor protein species precipitated by Ab 1-2 receptor is probably a receptor hybrid inasmuch as it was not present in cells overexpressing WT receptors which only were manifest as a 460-kD band, as expected.
The lack of an IGF-I inhibitory effect on pituitary GH secretion is coincident with the loss of endogenous wild type rat holotetramers in the cells overexpressing truncated (952STOP) human IGF-I receptors by the formation ofrat/human hybrid receptors. These hybrids are nonfunctional probably due to the fact that they consist of an intact and kinase defective af3 halfreceptor. These results demonstrate transdominant inhibition of ligand-dependent autophosphorylation and substrate phosphorylation by kinase inactive IGF-I half-receptors and are consistent with similar results shown for the insulin receptor ( 13, 21 ) . Co-expression of a truncated and wild-type plateletderived growth factor # receptor abolished receptor autophosphorylation, association of PI-3 kinase with the receptor and calcium mobilization so that the early steps in platelet-derived growth factor signal transduction were blocked ( 10). Similar dominant negative loss of function has also been reported for truncated epidermal growth factor receptors (8, 9 ) and a point mutant in the kinase domain of c-kit ( 12) .
The dominant negative concept, initially proposed by Herskowitz (22) could be extrapolated to dimeric ligands. Hybrid receptors provide a unique tool to evaluate tetrameric receptor functioning. Based on these results, overexpression of dominant negative IGF-I receptor mutants in transgenic mice may therefore represent a viable technique for targeted inactivation of human pituitary genes.
